Equities

4Basebio PLC

4BB:LSE

4Basebio PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)560.00
  • Today's Change0.00 / 0.00%
  • Shares traded2.00
  • 1 Year change-52.34%
  • Beta1.3953
Data delayed at least 20 minutes, as of Feb 06 2026 08:08 GMT.
More ▼

Financials data is unavailable for this security.

Inc stmt in GBPIncome statement in GBPView more

Year on year 4Basebio PLC had net income fall 60.90% from a loss of 7.67m to a larger loss of 12.33m despite a 84.39% increase in revenues from 506.00k to 933.00k. An increase in the selling, general and administrative costs as a percentage of sales from 766.40% to 884.14% was a component in the falling net income despite rising revenues.
Gross margin61.55%
Net profit margin-809.95%
Operating margin-819.62%
Return on assets-59.05%
Return on equity-209.34%
Return on investment-64.81%
More ▼

Cash flow in GBPView more

In 2024, 4Basebio PLC increased its cash reserves by 1,027.53%, or 31.54m. Cash Flow from Financing totalled 43.87m or 4,701.71% of revenues. In addition the company used 10.74m for operations while cash used for investing totalled 1.57m.
Cash flow per share-0.92
Price/Cash flow per share--
Book value per share1.23
Tangible book value per share0.981
More ▼

Balance sheet in GBPView more

4Basebio PLC appears to have little financial risk as the company holds a substantial amount of cash on its books. In fact, 0.40% of the market capitalization can be attributed to its 34.60m and debt could be paid in full if management chose.
Current ratio11.36
Quick ratio11.15
Total debt/total equity0.8132
Total debt/total capital0.4485
More ▼
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.